Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are excited to announce that Catherine Harmer, Susannah Murphy and Liliana Capitão are one of a select number of teams funded by Wellcome to review the evidence on which aspects of interventions really make a difference in preventing and treating youth anxiety and depression.

Image shows the Wellcome logo with the caption: Funded by Wellcome to advance science so no one is held back by mental health problems.

Each commissioned team will review the evidence for one active ingredient. The active ingredients are diverse and cover the range of options, from improving gut microbiome function to increasing financial resources via cash transfer, from the use of antidepressants to increased self-compassion.

Our team will look at the effects of SSRIs in young people.  SSRIs are used in this age group and are effective compared to placebo, though effects are relatively modest and concerns about the long term effects on the developing brain remain. During this commission, we will be reviewing the available evidence to present an insight analysis into what the evidence says about how, when and why SSRIs may be effective.

We will be meeting regularly with the other commissioned research teams to share learning and start to explore how the different active ingredients relate to each other.

Key to our success in the application process was our inclusion of the vital perspective of those with lived experience of mental health difficulties as part of our advisors.

In time, Wellcome wants to work with the mental health science community to refine and review these initial active ingredients to a core foundational set that we know work for the most young people, in the most contexts, globally. This set will underpin Wellcome’s work on advancing mental health science. For the first five years of the programme, it is committing £200m to finding the next generation of treatments and approaches for anxiety and depression in young people aged 14-24.


Wellcome believes it is vital we find the next generation of treatments and approaches that help young people with anxiety and depression worldwide. Anxiety and depression are holding millions of people back in life, generally starting in youth. Yet we still know too little about what works for whom, in what contexts, and why, in terms of either prevention or intervention.

To undertake iteration and innovation, Wellcome wants to identify what the ‘active ingredients’ are for the many treatments, therapies and social tools which already help young people through this commission. What are the facets of talking therapies which make them work for certain people? What are the physiological elements which enable people to self-manage their anxiety and depression? What are the social factors which allow people to escape from loneliness?

In some fields, the active ingredients of successful interventions are relatively clear cut. For example, two key interventions offered for the treatment of cancer are surgery or chemotherapy, and science has found the active ingredient of both is the destruction of cancer cells.

Founding the future of mental health science

Through this commission, our team are founding members of the community advancing mental health science that Wellcome are building. Together, we are collectively focused on looking at the issue through a new lens: that of the ‘active ingredients’ of interventions that work.

Professor Miranda Wolpert, Head of the Mental Health Priority Area at Wellcome, says:

“We are delighted to be working with such a wonderful range of researchers worldwide to study which aspects of interventions really make a difference in preventing and treating youth anxiety and depression. We see this commission into reviewing the evidence for active ingredients of interventions as the crucial first step in finding the next generation of treatments and approaches for tackling youth anxiety and depression across the world.”

Grace Gatera, a Lived Experience Mental Health Advocate living in Kigali, was part of the application review team. She says:

“The successful proposals have really touched something in me, as they make lived experience a priority in research and are focused on the end user. I’m looking forward to the work the teams are going to do that pave the way for a future of affordable, accessible mental health care for all young people worldwide, including those from low resource settings”.


We are delighted to be part of this insight review and start to address this really important area for adolescent mental health.  SSRIs are widely prescribed across ages and yet there is little scientific work exploring how they work in young people and the effects underlying both the therapeutic and unwanted effects of treatment.Professor Catherine Harmer, team lead, Department of Psychiatry, University of Oxford.


The commission begins today and we will report our findings in October 2020.

Find out more about Wellcome’s priority mental health programme here.


Please follow the link below to read the news on the NIHR BRC website.

Similar stories

How Mindfulness May Improve Body Satisfaction and Mood

New research from Emma Osborne, Research Assistant at the Centre for Research on Eating Disorders (CREDO) at the University of Oxford (and PhD Candidate at the University of Bath), and Dr Melissa Atkinson, University of Bath, investigated two ways in which mindfulness might improve body satisfaction and mood.

Review Highlights Risk Factors Associated with Violence in Schizophrenia

Researchers at Oxford University’s Department of Psychiatry have found that people with schizophrenia and related disorders are at higher-than-average risk of perpetrating violence, but that the overall risk remains low (less than 1 in 20 in women, and less than 1 in 4 for men over a 35-year period for violent arrests and crimes).

New Study will Investigate Brain Fog Symptoms in Post-Hospitalised COVID-19 Patients

C-Fog is a collaborative new study led by Oxford University researcher, Dr Maxime Taquet, which will investigate the reasons why brain fog or cognition problems affect patients after COVID-19 infection. With a better understanding of the mechanisms involved it may be possible to understand how to treat brain fog and help many thousands of people worldwide.

A New Experimental Study Investigated the Effects of Atorvastatin on Emotional Processing

Atorvastatin is one of a group of statins widely used to treat heart and blood vessel diseases. The medication works by lowering cholesterol in the blood. This new study shows that atorvastatin influences the way people experience certain emotions, giving us important insights about disorders such as anxiety and depression.

People with Long-COVID After Hospitalisation Face Limited Recovery After One Year

People who were hospitalised with COVID-19 and continued to experience symptoms five months later, show limited further recovery one year after hospital discharge, according to the latest results of a major national study looking at the long-term health impacts of COVID-19 on hospitalised patients.

The Effects of Social Media on Public Attention and Attitudes Towards COVID-19 Vaccines in the UK

A new study finds that media coverage of positive vaccine research can have a positive effect on overall social media sentiment, countering vaccine misinformation, but the effects wane over time.